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Abstract
Recent research suggests that the nation’s water supply is contaminated with trace pharmaceuticals
that exert a negative environmental and public health impact. Incorrect medication disposal meth-
ods (e.g. flushing medications down the toilet or drain) are a significant factor contributing to the
presence of medication compounds in the aquatic environment. In this commentary, we provide a
summary of the existing data on pharmaceuticals in the nation’s water as well as the role of
improper medication disposal methods on water contamination.We discuss statistics on improper
medication disposal practices among patients and clinicians as well as recent advances in proper
medication disposal methods as a solution to this problem. Currently, many patients and clinicians
are not aware of proper medication disposal practices. We summarize the importance of patient
and clinician education in advancing environmental-safe medication disposal methods.
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Introduction: Medications in the
United States water supply
In January of 2014, a study published by
Environmental Pollution revived public
attention on a problem that has been
researched for decades – namely, pharma-
ceuticals in the water supply.1 A study that
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measured the concentration of 56 active
pharmaceutical ingredients across 50 large
wastewater treatment plants found that
hydrochlorothiazide, a diuretic that treats
high blood pressure, was in every sample.2
Other high blood pressure medications (e.g.
metoprolol and atenolol) and the mood sta-
bilizer carbamazepine were found in more
than 90% of the samples.2 With media out-
lets citing the study as the most extensive
study of water coming out of wastewater
treatment plants,1 these results garnered
global attention. Since the study’s publica-
tion, environmental lawyers have been call-
ing for increased tests on water supplies
with the aim of determining the public
health impact of these pharmaceuticals.
Concern exists that even trace quantities
could lead to detrimental health impacts
for humans such as antibiotic resistance
and abnormal hormonal effects among
teenagers.1,3 Pharmaceutical residues may
also interfere with the reproduction and
growth of aquatic life.3
Drinking water treatment has a long and
intricate history. For ancient civilizations,
water treatment centered on aesthetics
(e.g. taste, odor, and appearance).4 By
4000 BC, methods were noted to improve
the taste and smell of drinking water.
Particles in water sources were seen as prob-
lematic only in that they interfered with the
water’s appearance and taste.4 It was not
until the mid to late 1800s that scientists
first realized the potential hazardous
impact of such particles on human
health.4 Louis Pasteur’s ‘germ theory’ of
disease, developed in the late 1880s, estab-
lished that microbes could spread disease
through water.4,5
Throughout the late nineteenth and early
twentieth centuries, concern increased over
the possibility that water particles could
carry pathogens. It was not until 1914, how-
ever, that federal regulation of drinking
water commenced with the US Public
Health Service establishing guidelines for
drinking water quality.4,6 These guidelines
were no longer sufficient by the late 1960s
when man-made chemicals began to enter
water sources through discharges from
industrial sources and underground tanks
(e.g. disposal and storage tanks), among
other contamination mediums.4 This ulti-
mately led to the passage of the Safe
Drinking Water Act (SDWA) in 1974.4
The SDWA and its subsequent amend-
ments have served as the primary means
from which drinking water regulations are
created to promote optimal drinking water
treatment and delivery.7,8 However, though
the number of water systems applying treat-
ment to their water sources has increased
since the passage of this act, water treat-
ment still does not effectively prevent indi-
viduals from exposure to harmful toxins
and chemicals in their drinking water.
Data collected supports that millions of
Americans drink water that is contaminated
with trace concentrations of pharmaceuti-
cals. As more tests are conducted by state
and federal agencies, a wide range of phar-
maceuticals (e.g. anticonvulsants, mood
stabilizers, hormones, and antibiotics)
have been discovered in the drinking water
supplies of at least 46 million Americans.9
For many years, research studies have
found traces of active pharmaceutical ingre-
dients (APIs), medicines, and synthetic hor-
mones in surface waters.10,11 Research
indicates that pharmaceuticals also enter
underground aquifers that supply 40% of
the water supply in the US.3 In one exper-
iment conducted across 24 states that exam-
ined water from aquifers located near
sources of contamination (e.g. landfills,
animal feed lots), small amounts of hor-
mones and antibiotics were discovered,
among other medications.3 An examination
by the US Geological Survey and the New
York State Department of the water supply
in upstate New York determined trace con-
centrations of heart medicine, estrogen,
928 Journal of International Medical Research 46(3)
antibiotics, a tranquilizer, anti-convulsants,
and a mood stabilizer.3
Medications flushed down the toilet or in
drains are one means through which chem-
icals pass through the sewer system and
enter our streams, lakes, and rivers.12
Indeed, pharmaceutical traces have been
shown to withstand standard water treat-
ment methods.13 Excretion is one route
through which APIs are believed to enter
wastewater systems as only a small amount
of consumed medication is fully absorbed
by the body.2,14,15 In septic systems, phar-
maceutical substances enter groundwater
and, in sewage systems, compounds are
directed to treatment facilities that are not
capable of fully degrading pharmaceutical
compounds. Together, these factors con-
tribute to wastewater that contains pharma-
ceutical residues.15,16 Bottled water and
home filtration systems do not necessarily
prevent exposure to these residues. Both
bottlers and home filtration system compa-
nies often do not treat or test for pharma-
ceuticals in the manufacture of their
products.3
One possible solution to the environmen-
tal impact of medications in the water
supply lies in the existence, instruction,
and implementation of proper medication
disposal methods.
Proper medication disposal:
an environmental solution
Research suggests that disposal of medica-
tions in the sink or toilet may significantly
lead to the presence of pharmaceuticals in
the aquatic environment.15,17 Thus, over the
years, several surveys have been conducted
to supply further insight into medication
disposal practices within the US.
Overall, findings from these surveys
suggest that a proportion of Americans
continue to employ incorrect methods of
medication disposal. However, these data
also demonstrate a trajectory towards
reduced methods of improper disposal
(e.g. unsafe practices such as flushing med-
ications down the toilet or sink, discarding
medications in the garbage). A survey of
500 callers to the Pittsburgh Poison
Center, the state Boards of Pharmacy, the
Food and Drug Administration, the
Environmental Protection Agency, and
community and hospital pharmacies on
their disposal practices for expired medica-
tions found that 35.4% flushed their medi-
cations down the toilet or in the sink and
1.4% brought their medications back to a
pharmacy.18 A survey of 301 individuals at
an outpatient pharmacy about their medi-
cation disposal practices and their beliefs
about medication disposal found that over
50% of the sample reported flushing their
medications down the toilet.19 A study that
attempted to survey 586 urology surgery
patients on their disposal of prescribed nar-
cotics post-surgery found that among the
275 survey respondents, less than 1% of
patients with remaining, unused medica-
tions returned the medications to a pharma-
cy.20 A web-based survey of medication
disposal practices and beliefs that was deliv-
ered to 138 hospice home care nurses found
that 55% of the nurses reported disposing
of medications via the sewerage system
on an ‘always’ or ‘often’ basis.21 Of note,
the nurses expressed concern about the
environmental impact of discarding medi-
cations to sewerage.21 Recently, a survey
conducted on medication disposal practices
of Medicare members found that 11% of
medications were discarded through medi-
cation take-back programs and 9% of med-
ications were flushed down the toilet.22
Environmentally unsafe disposal practi-
ces are also common outside of the US. A
survey conducted among Serbian house-
holds (n¼ 383 families) on their methods
of storing and discarding of expired medica-
tions found that 82.8% of survey respond-
ents employed an incorrect medication
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disposal method (e.g. disposing of expired
medications in the garbage), whereas only
4.4% of respondents used a correct medi-
cation disposal method (e.g. bringing
expired medications to a pharmacy).23 Of
note, though a large percentage of survey
respondents used improper medication dis-
posal methods, 66.3% of survey respond-
ents were aware that throwing medications
in the garbage could have a detrimental
impact on the environment.23 Similarly, a
2016 survey of individuals living in China
found that the majority of survey respond-
ents disposed of pharmaceuticals in the
garbage.24
What factors have influenced improve-
ments in medication disposal practices?
The Secure and Responsible Drug
Disposal Act of 201025 allowed for an
amendment of the Controlled Substances
Act (CSA),26 which regulates distribution,
importation, manufacture, possession, and
use of controlled substances. The rise in
nonmedical prescription medication use
in the US, especially among teenagers, as
well as unintentional overdose mortalities
involving prescription opioids, motivated
the adoption of this amendment, among
other factors.27 Under this amendment,
the Drug Enforcement Administration
(DEA) was given authority to create regu-
lations and propose new options for proper
medication disposal. These regulations
include medication take-back programs,
medication mail-back programs, and collec-
tion receptacles for medication disposal.
Prior to the passage of this amendment,
the CSA did not supply a means for
patients to discard controlled substances
(e.g. unused prescription medications);
pharmacies and medical facilities were
legally not allowed to accept controlled sub-
stances for disposal. As a result, many indi-
viduals employed incorrect medication
disposal methods, such as discarding medi-
cations in the garbage or flushing them
down the toilet.28 The DEA’s Final Rule
on 9 October 2014 effectively implemented
the Secure and Responsible Drug Disposal
Act of 2010.29 Under this regulation, phar-
macies and healthcare facilities have the
option to register as designated collection
sites for any unwanted medications.30
As of February 2016, options for proper
medication disposal have been established
in multiple community locations and phar-
macies across the US with 882 DEA regis-
trants labeled as designated collectors.30
Over the last few years, published studies
have suggested public interest in these pro-
grams as well as the potential of these
programs to reduce nonmedical use of
prescription medications and the environ-
mental impact of improper medication dis-
posal.31–33 A survey was conducted to
determine the level of interest patients
had for participating in a community
pharmacy-based medication take-back pro-
gram for disposal of unused, unwanted, or
expired (UUE) medications. Of the 62
survey respondents, 61% reported interest
in participating in a medication take-back
program, while 57% reported having
no UUE medications at home.32 Of note,
the authors suggest that awareness of
environmental-safe methods of medication
disposal remains limited.32 More recently,
a study examined prescription opioids
returned for disposal to a Wisconsin medi-
cation take-back program.31 The study
found that, among returned opioid pre-
scriptions, more than 60% of the dispensed
amount was unused, suggesting that medi-
cation take-back programs could be effec-
tive in eliminating unused medications from
the home environment.31 Another study
reported the success of a medication take-
back program in North Carolina that
hosted more than 1395 take-back events
between 2010 and 2014.33 During this time
frame, there was a 597% and 35.8%
increase in the number of participating
law enforcement agencies and counties,
respectively.33 Similar success was reported
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for prescription medication take-back
efforts based in eleven Maine cities during
six DEA national medication take-back
events from 2011 to 2013.34 Controlled pre-
scription medications comprised 9.1% of
returned medications, over-the-counter
(OTC) medications comprised 31.4% of
returned medications, and non-controlled
prescription medications comprised 56.4%
of returned medications.34 The effectiveness
of an UUE collection campaign event in
New Jersey was reported; the campaign
event reached 60% of its intended audience
and campaign exposure was associated with
bringing UUE medication to a collection
site for proper disposal, having conversa-
tions with other individuals about medica-
tion disposal, and instructing children on
the dangers of prescription drug abuse.35
Instruction on proper medication
disposal: A key factor
As a result of the 2014 DEA ruling, resour-
ces for medication disposal have increased
in recent years. However, data from several
research studies suggest that instruction on
proper disposal methods warrants further
emphasis and attention. A 2006 survey of
patients at an outpatient pharmacy found
that under 20% of the sample had received
instruction about medication disposal by
their clinician.19 Of note, prior instruction
on proper medication disposal was highly
associated with returning medications to a
pharmacy and was the factor most strongly
associated with returning medications to a
clinician.19 Ten years later, instruction on
proper medication disposal remains an
area for improvement.32,36–38 For instance,
a survey of 300 adult cancer outpatients
assessing patterns of storage, use and dis-
posal of opioids found that 74% of the
sample was not informed on proper means
for disposing of opioids.36 A survey study
of 586 urology surgery patients found that
92% of patients reported receiving no
instruction on disposal practices for extra,
unused medications.20 Researchers cite the
important role of the pharmacist as educa-
tors for patients on proper medication dis-
posal practices,32,37,38 with many noting
that lack of awareness of medication take-
back programs provides pharmacists with
the opportunity to inform themselves
and the general public on medication dis-
posal practices.32,37 Indeed, pharmacist-
or clinician-delivered patient instruction
on proper medication disposal could fur-
ther reduce the widespread environmental
and public health ramifications created by
unsafe disposal practices.32,39 However,
some researchers note a barrier to this
instruction – specifically, many pharmacists
and clinicians may not possess knowledge
on proper medication disposal. A survey
of 142 pharmacists in California exploring
their awareness of proper medication dis-
posal practices as well as their intention to
provide education on these practices found
that, while most pharmacists indicated a
positive intention to provide education,
they supplied this education on an infre-
quent basis (e.g. once a month or less).38
Further, only a small percentage of the
sampled pharmacists correctly selected
appropriate recommendations for disposing
of controlled (10.1%) and non-controlled
(15.9%) substances.38 A survey on medica-
tion disposal practices among hospice care
nurses found that only 16% of the surveyed
sample reported learning about safe medi-
cation disposal practices in their nursing
training programs.21 Future initiatives on
medication disposal education may benefit
from informing not only patients but also
clinicians and pharmacists. It may also be
necessary to implement improved education
programs on proper medication disposal in
nursing and medical education programs.
Table 1 summarizes key findings across
studies exploring medication disposal
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practices and medication take-back pro-
grams in the US.18–22,31–36,38
Clinical relevance of proper medication
disposal methods
Enhancing the widespread application of
correct medication disposal procedures
will not only yield important environmental
benefits but also has the potential to reduce
the US’s widespread problem with prescrip-
tion or OTC drug abuse and misuse.40
Misuse of prescription and OTC medica-
tions is unfortunately quite widespread;
across several large samples, approximately
12–17% of American teenagers report inap-
propriate use or abuse of such medications
(e.g. use of medications without a prescrip-
tion, excessive use of medications).40–42 In
some cases, such misuse or abuse has been
linked to the presence of unused medica-
tions left in household cabinets and to the
passing of unused medications to other
individuals as a means of disposal (an
action that can lead to drug abuse or
misuse by the medication recipient).40,43,44
Recently, we explored the role of unsafe
and/or lack of medication disposal practices
in the development of prescription and
OTC drug abuse and misuse in the US;40
in our manuscript, we proposed a three-
part mechanism for reducing abuse of
prescription and OTCmedications that inte-
grates elimination of social stressors in the
environment, continued creation and expan-
sion of medication take-back programs, and
increased education on proper medication
disposal practices across patient, caregiver,
and clinician communities. This model can
also be applied toward reducing the environ-
mental damage created by unsafe medica-
tion disposal practices. By increasing and
improving education on medication dispos-
al practices, enhancing existing medication
take-back programs, and creating new
medication-take back programs, incorrect
medication disposal practices can be
significantly curtailed.40 Reductions in
improper disposal practices will, in turn,
lead to a diminished presence of medications
in the water supply and, thus, reduced
destruction to the environment.
Conclusion
Data suggests that pharmaceuticals exist in
the US water supply and that the presence
of these compounds can partially be attrib-
uted to improper medication disposal prac-
tices.2,9,15,17 In 2014, a DEA ruling created
options for proper medication disposal such
as take-back programs, collection recep-
tacles, and mail-back programs.29 A 2010
manuscript noted that the impact of medi-
cation take-back programs remained to be
determined.45 In the past few years, medi-
cation disposal programs and events have
been implemented and broadly utilized.33,34
For disposal of hospital medications,
hospital-based pharmacies that accept
unused medications should continue to be
broadly implemented.46 Given their wide-
spread presence, these programs have the
potential to significantly reduce the negative
environmental impact caused by improper
medication disposal. Future efforts should
focus on the continued creation of medica-
tion disposal programs across the US as
well as on overcoming barriers to program
implementation. These barriers include the
cost burden associated with take-back pro-
grams as well as potential difficulties in
obtaining appropriate collection recep-
tacles.47 Of note, one recent analysis sug-
gested that, relative to other sources of
pharmaceutical excretion to the environ-
ment, incorrect medication disposal meth-
ods only minimally contribute to
environmental damage.48 Nonetheless,
enhancing safe medication disposal practi-
ces is an important way to help reduce any
environmental threat, regardless of the
magnitude of this threat.48
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Currently, many clinicians and patients
lack instruction in and awareness of
proper medication disposal practices.21,36,38
The upcoming challenge is to disseminate
widespread medication disposal education
programs for both patients and caregivers
into the community. Targeted sessions with
a particular focus on the environmental
effects of improper disposal may help elim-
inate pharmaceuticals and medication com-
pounds from our water supply.
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